WCG Wealth Advisors LLC Makes New Investment in DexCom, Inc. $DXCM

WCG Wealth Advisors LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, HoldingsChannel reports. The firm purchased 30,734 shares of the medical device company’s stock, valued at approximately $2,040,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of DexCom by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock valued at $3,327,897,000 after purchasing an additional 1,133,638 shares during the last quarter. Geode Capital Management LLC raised its position in shares of DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares in the last quarter. Norges Bank purchased a new position in DexCom during the fourth quarter worth approximately $483,356,000. CIBC Private Wealth Group LLC lifted its position in shares of DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock valued at $195,666,000 after acquiring an additional 2,294,709 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of DexCom by 4.7% in the third quarter. Legal & General Group Plc now owns 2,635,700 shares of the medical device company’s stock valued at $177,356,000 after acquiring an additional 117,493 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 42,694 shares of company stock valued at $3,029,267. 0.28% of the stock is owned by corporate insiders.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

DexCom Trading Up 0.4%

NASDAQ:DXCM opened at $72.86 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The business’s 50-day simple moving average is $64.83 and its 200 day simple moving average is $66.98. The stock has a market cap of $28.11 billion, a price-to-earnings ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 earnings per share. As a group, sell-side analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DXCM shares. Sanford C. Bernstein set a $77.00 target price on DexCom in a research report on Friday, May 1st. Stifel Nicolaus set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday. Citigroup reaffirmed a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Bank of America reduced their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, Robert W. Baird set a $80.00 price objective on DexCom in a research note on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.63.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.